Atogepant

Atogepant

Clinical data
Trade names	Qulipta
Other names	AGN-241689, MK-8031
License data	US DailyMed: Atogepant
Routes of administration	By mouth
ATC code	N02CD07 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
CAS Number	1374248-81-3
PubChem CID	72163100
DrugBank	DB16098
ChemSpider	59718640
UNII	7CRV8RR151
KEGG	D11313
ChEMBL	ChEMBL3991065
Chemical and physical data
Formula	C29H23F6N5O3
Molar mass	603.525 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
InChI InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1 Key:QIVUCLWGARAQIO-OLIXTKCUSA-N

Atogepant, sold under the brand name Qulipta, is a medication used to prevent migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.

It was approved for medical use in the United States in September 2021.

Medical uses

Atogepant is indicated for the preventive treatment of episodic migraine in adults.

Research

A study found that atogepant reduced the number of migraine days over twelve weeks.

External links

• "Atogepant". Drug Information Portal. U.S. National Library of Medicine.